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A B S T R A C T
Objectives: The aims of this analysis were to confirm the UK results in other countries and
to explore the possibility of subscales of the 25-Item Macular disease Dependent Quality of
Life (MacDQoL) questionnaire.
Methods: Two clinical studies were pooled. Principal components analyses (Varimax) were
conducted on baseline data from each country and from all combined. Factorial structures
were compared between countries, and Cronbach alpha values were used to identify item
clusters. Four groups of patients were created according to visual acuity (VA) in the best eye
(BE10/20; BE10/20) andworst eye (WE10/100;WE10/100). These groups were used to
investigate (analysis of variance) the sensitivity of MacDQoL to VA impairment and to com-
pare it with the NEI-VFQ-25 generic visual function questionnaire.
Results: A total of 797 patients (mean age 76.8 years; 55.8%women) had wet age-relatedmac-
ular degeneration (AMD). Strong correlations between theMacDQoL items (r 0.48) and factor
loadings0.49ona forcedone-factor analysis supported theuseof anaverageweighted impact
score. Four constructs (Cronbach alpha0.8) were derived, represented by the labels: Essential
tasks, Family/social life,Activities/capabilities, andEmbarrassment.Thestructuredidnotdiffer
among the four countries involved, except one item (Finance), which has been excluded. Pa-
tients with BE VA10/20 andWE VA10/100 produced significantly worse overall scores than
those with BE VA10/20 andWE VA10/100 (MacDQoL P 0.0001; NEI-VFQ-25 P 0.0001).
Conclusions: The analysis confirmed the metric properties of the MacDQoL. The MacDQoL
offers a broad individualized measure of the impact of MD on quality of life.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). Published by Elsevier Inc.
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111V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 – 1 2 0ntroduction
ge-related macular degeneration (AMD) affects the central
ortion of the retina (macula) responsible for central vision.
s opposed to peripheral vision, central vision is essential
or driving, reading, face recognition, and fine visual tasks
1]. The disease occurs in two forms, atrophic (or dry) AMD
haracterized by localized atrophy and exudative (or wet)
MD characterized by choroidal neovascularization (CNV)
2]. Atrophic AMD is more frequently encountered than the
xudative form. Atrophic AMD progresses slowly over a
ariable period, usually 5 to 10 years, and eventually results
n legal blindness (visual acuity 20/200). In contrast, exu-
ative AMD affects no more than 10% to 20% of patients
ith AMD, in general, but presents a far greater threat to
ision, accounting for 80% to 90% of all blindness in these
atients [3].
AMD is the most common cause of all adult blindness in
estern developed countries [4,5] and is the major reason
or severe vision loss in people above 65 years of age [6,7].
nd-stage (blinding) AMD is found in about 1.7% of all peo-
le older than age 50, and incidence rises with age (0.7% to
.4% in people age 65 to 75, 11.0% to 18.5% in people older
han age 85) [8]. The 5-year incidence rate of late-stage AMD
as estimated as between 0.49% and 1.1% [9–12]. AMD in-
idence rate is increasing exponentially with age [13]. The
urden of ocular morbidity and visual disability due to AMD
ill increase further with an expanding older population
13]. A steady increase in the number of people now regis-
ering as blind/severely sight impaired in the UK [14] sug-
ests that the incidence of AMD is already growing in most
estern populations [13]. As a result, AMD is an increasing
ublic health concern for decision makers.
Awareness of the impact of AMD on quality of life (QoL)
emains low among clinicians and the general public and,
s pointed out elsewhere [15], considerable confusion is
aused by the misuse of health status tools and utilities to
easure QoL in people with AMD. In a direct comparison of
time trade-off (TTO) utilitiesmeasure with scores from the
acular disease Dependent QoL (MacDQoL) questionnaire,
itchell and Bradley [16] found that TTO was not a valid
ndicator of QoL in this elderly population whose willing-
ess, or, more often, unwillingness to trade years of life was
nfluenced by many factors other than the severity of their
D. TTO also has been shown to be unrelated to visual
cuity by Hill et al. [17], who showed that 50% of partici-
ants with varying severity of MD were unwilling to trade
ny time for perfect vision. For those who would trade some
ime, there was no relationship between TTO and visual
cuity. We suggest that health status instruments are inap-
ropriate also, because they can measure only perceived
ealth, not QoL, and respondents will not necessarily even
onsider their vision when rating their health [15]. It is not
nusual for individuals who are registered blind to report
hat they have excellent health on measures such as the
Q-5D and SF-36 while nevertheless reporting severe im-
airment to their QoL as a result of their vision loss. MAMD has been shown to be associated with significantly
mpaired scores using the NEI-VFQ-25measure of visual func-
ion [18] and the Quality of Well-being Scale [19]. Functional
ndependence also has been shown to be negatively impacted
s measured by the Instrumental Activities of Daily Living in-
ex, self-rated general health status, the Profile ofMood States
8,20,21], and other patient-reported outcome measures [15].
eople with AMD are particularly susceptible to depression
15,22,23]. Also, visual impairment is strongly associated with
ncapacity, dependency [24,25], and institutionalization [26].
isual function (measured with the NEI-VFQ-25) deteriorates
s soon as the first eye is affected in AMD patients [18] or in
atients with other types of eye diseases [27], though the as-
ociation between visual function and best eye (BE) vision re-
ains strongest [18]. Although visual function measures (e.g.,
EI-VFQ-25 [18]) and well-being (e.g., the Well-being Ques-
ionnaire W-BQ12 [19]) are likely to correlate to some degree
ith QoL, they are not in themselves measures of QoL. Fin-
er et al. [28] in 2008 and van Nispen et al. [29] in 2009
rovided useful reviews of vision-specific questionnaires
vailable for people who have AMD. Although Finger et al.
ntitled their article “Quality of Life in Age-Related Macular
egeneration,” in fact most of the measures included in the
eview are measures of visual function. Few measures used
n studies of AMD actually measure QoL, although the
acDQoL is an exception [30].
Treatments are now available for wet AMD [31–34]. Pub-
ic health authorities are increasingly insisting that patient-
eported outcome assessment [35] be included in trials eval-
ating new treatments; many have demanded health status
easures such as the EQ-5D [36], but these have been
hown to be unsuitable for evaluating the impact of AMD on
oL [15]. The need for a valid instrument to measure the
mpact of AMD on QoL led to the development of an indi-
idualized questionnaire specific tomacular disease includ-
ng AMD. The resulting MacDQoL questionnaire [37,38] asks
bout the impact of MD on aspects of life that have personal
elevance for the individual and the importance of those
spects of life for their QoL. The strategy of weighting QoL
omains on the basis of their importance to an individual
as previously adopted in an interview method developed
y McGee et al. [39] and was adapted for questionnaire use
y Bradley et al. with the diabetes-specific Audit of Diabetes
ependent QoL [40,41], which provided a model for the
acDQoL. Bradley et al. [39] followed McGee et al. in defin-
ng QoL as “how good or bad you feel your life to be,” and it
s this definition that is included in the instructions for com-
letion of the Specific Audit of Diabetes Dependent QoL,
acDQoL, and related measures. The design [37] and psy-
hometrics [38,42] of the MacDQoL questionnaire are pub-
ished elsewhere. In a sample of UK patients, the MacDQoL
howed excellent internal consistency reliability, test-re-
est reliability [38,43], and a single-factor structure. The
acDQoL showed that macular degeneration has a consid-
rable negative impact on many aspects of life important
or QoL [37,42]. To be used in multinational clinical trials,
he instrument requires validation in other languages. The
im of this article is to report the factorial structure of the
acDQoL in French, German, Italian, and American AMD
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112 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 – 1 2 0atients and to explore the possibility that there may be
seful subscales.
aterial and Methods
nstitutional reviewboard or ethics committee approvalswere
btained by all centers participating in a clinical trial that con-
ributed data to the present analysis. Written informed con-
ent was obtained from all patients, and investigations per-
ormed in the United States were Health Insurance Portability
nd Accountability Act–compliant (HIPAA).
Concerning the cross-sectional survey, institutional review
oard approval was obtained in Germany and Italy. In France,
he protocolwas reviewedby theComitéConsultatif sur le Trait-
ment de l’Information en matière de Recherche dans le do-
aine de la Santé. Informed consent was obtained from all pa-
ients.
ata sources
he reported analyses were performed on baseline data ob-
ained from a randomized clinical trial and a separate cross-
ectional survey. The experimental design of the clinical trial
s published elsewhere [33]. The trial was conducted according
o a prospective, randomized, double-masked, multicenter,
arallel-group, active-controlled, and noninferiority design. It
ompared photodynamic therapy (with anecortave acetate, 15
g) at centers in the United States, Canada, Italy, The Neth-
rlands, Belgium, Spain, Israel, and Australia. Enrolled pa-
ientswere of any race, either sex, and agemore than 50 years,
rovided they alsomet criteria that included clinical diagnosis
f AMDmanifesting as a predominantly classic subfoveal CNV
esion in the study eye (either primary or recurrent after laser
hotocoagulation) and, at the screening visit, a best-corrected
isual acuity between 0.30 LogMAR (20/40 Snellen) and 1.30
ogMAR (20/400 Snellen) in the study eye, which conforms to
he Early Treatment Diabetic Retinopathy Study. Responses
o the MacDQoL questionnaire were elicited by telephone
uring the 2 days after the baseline visit. In total, 530 pa-
ients were enrolled. The NEI-VFQ-25 was not included in
his trial. The full files of the trial were accessed, but we
sed only baseline data (before randomization) for the cur-
ent analysis. Their average age was 76.6 years (range 51 to
6 years). Most patients were Caucasian (98%), and 52%
ere women. Mean baseline visual acuity was 0.72 logMAR
nits (20/100 Snellen).
In addition, patient data were obtained from the Microeco-
omic Impact of Macular Disease survey, conducted in three
ountries (France, Germany, and Italy) [23,44,45]. The design
as multicenter, cross-sectional, and stratified by level of
MD severity. The survey assessed QoL and the consumption
f medical and nonmedical resources by a sample of patients
ith AMD (exudative, wet form). Clinical data were collected
etrospectively and during a consultation visit. Patients com-
leted questionnaires at the end of the visit andwere required
omeet the following criteria: 1) age50 years; 2) consultation
or exudativeAMD (i.e., predominantly classic, subfoveal CNV,
ocumented by clinical notes, fundus photography, and fluo- cescence angiography); 2) consent to medical dossier access
or relevant information; 3) able to answer the questionnaire,
ither personally or with the aid of a caregiver; and 4) consent
o participate in the survey. Data collection included: 1) patient
ociodemographics; 2) AMD history; 3) visual acuity (each eye)
nd binocular vision, at diagnosis and at the visit; 4) MacDQoL
eplies; and 5) NEI-VFQ-25 replies. Three hundred sixty patients,
ostly women (60%), were enrolled. Their mean age was 77
ears, and themean time elapsing since AMD diagnosis was 2.3
ears. On the day of the visit, mean VAwas 0.49 LogMAR for the
E and 1.0 LogMAR for the worst eye (WE).
Validation of the MacDQoL was based on data from coun-
ries with population samples sufficiently large to allow pre-
ise country estimates. Countries included were France, Ger-
any, Italy, and the United States.
acDQoL
he MacDQoL individualized measure of the impact of macu-
ar disease on QoL begins with two single-question overview
tems that investigate present QoL and the impact of MD on
oL. Twenty-three items follow which each investigate spe-
ific aspects of life. Each item has two parts; the first part asks
bout the impact of MD on that aspect of life and the second
art asks about the importance of that aspect of life to the
ndividual’s QoL. The two scores are multiplied together to
ive a weighted impact score. Some items have a preliminary
uestion that acts as an inapplicable option (e.g., working life).
n average-weighted impact score is obtained by summing
he weighted impact scores and dividing by the number of
pplicable items. The language versions other than English
sed in the present studywere linguistically validated, includ-
ng cultural adaptation, by Mapi Research Institute from the
riginal English with two forward translations, reconciliation,
ack translation, review, and discussion with the developer
nd further translation and back translation as needed, re-
iew of terminology by ophthalmologist, and international
armonization with other language versions. Cognitive de-
riefing interviews were conducted during design work of the
riginal UK English version, and during the linguistic validation
rocess for the Italian version before use, but few substantive
hangesweremade to the Italian as a result of these interviews.
o cognitive debriefing interviews were conducted in France,
ermany, or the United States before the use of the question-
aires in the work reported here. The US English was adapted
rom the UK English by a native US English consultant living in
heUnited States before reviewby ophthalmologist and interna-
ional harmonization.
tatistical analysis
tatistical analyses were performed with SAS software release
.1.3. (SAS institute; Cary, NC, USA). The current work is a con-
rmatory factorial analysis (CFA) of the exploratory factorial
nalyses (EFA) performed by Mitchell et al. [42]. Therefore, the
trategy was to focus the confirmatory analysis on a four-factor
olution. This follows the principles stated by Brown [46]: al-
hough both EFA and CFA are based on the common factor
odel and often use the same estimation method, the specifi-
ation of CFA is strongly driven by theory or prior research evi-
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113V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 – 1 2 0ence.Thus,unlike theapproach inEFA, inwhich the researcher
an only prespecify the number of factors, the CFA researcher
sually tests a much more parsimonious solution by indicating
he number of factors and the pattern of factor loadings.
Principal components analysis (PCA with Varimax rota-
ion) was used to compare the four-factor structure initially
eported to have been found in exploratory analyses byMitch-
ll et al. [42]. Accordingly, four factors were forced. Analyses
ere performed on the whole sample and on each country
eparately. Comparisons were performed using linear struc-
ural equation modeling (SAS Proc Calis). The response cate-
ory Not applicable was analyzed twice: first, by recoding the
ot applicable response as zero; and second, by listwise dele-
ions of participants withmissing data. Lastly, PCAs were per-
ormed on raw data and the correlation matrix, with coeffi-
ients estimated pairwise to minimize missing data effects.
Three items (Table 1) were not included in the analysis
ollowing the findings reported by Mitchell et al. [42] and con-
rmedwith our data. Originally,Work (item#4)was applicable
o very few people andwas not included in the weighted over-
ll score because the factor structure and reliability could not
e assessed with Work included; it was examined separately.
ong journeys (item #11) were strongly correlated with Holi-
ays (item #12), and this itemwas excluded. Society’s reaction
Table 1 – Principal component analysis (PCA) according to
Item no. Description* P
MacD1 Household tasks
MacD2 Personal affairs
MacD3 Shopping
MacD4 Work
MacD5 Personal relationship
MacD6 Family life
MacD7 Social life
MacD8 Physical appearance
MacD9 Do physically
MacD10 Get out and about
MacD11 Long journeys
MacD12 Holidays
MacD13 Leisure activities
MacD14 Hobbies
MacD13&14 Leisure activities, hobbies
MacD15 Self-confidence
MacD16 Motivation
MacD17 People’s reaction
MacD18 Society’s reaction
MacD19 Future
MacD20 Finances
MacD21 Independence
MacD22 Do for others
MacD23 Mishaps
MacD24 Enjoy meals
MacD25 Time taken
MacD26 Enjoy nature
C1: Essential tasks (F1 in Mitchell et al.); C2: Family/social life (F4 i
comparisons); C3: Activities/capabilities (F2 in Mitchell et al. referred
referred to as C4 here in the final column); PCA 1: patients with mis
pairwise deletion; PCA 3: suppression of item 12.
* Item descriptions come fromMitchell et al. [42], as do the construct
column.item #18) was dropped because of poor comprehension. aastly, Hobbies (item #14) and Leisure activities (item #13)
ere merged into one item because they were tapping into
ery similar experiences.
ssessment of unidimensionality
he backward Cronbach Alpha Curve (CAC) is an essential
onfirmatory tool to assess the unidimensionality of the set of
tems. It is performed after the exploratory step, and it allows
s to confirm definitively the best item clustering.
The Spearman-Brown formula indicates a simple relation-
hip between CAC and the number of variables. It is easy to
how that the CAC is an increasing function of the number of
ariables. This formula is obtained under the parallel model.
A step-by-step curve of CAC can be built to assess the one-
imensionality of a set of variables [47,48]. The first step uses
ll variables to compute CAC. Then, at every successive step,
ne variable is removed from the scale. The removed variable
s the one that leaves the scale with its maximum CAC value.
his procedure is repeated until only two variables remain. If
he parallel model is true, increasing the number of variables
ncreases the reliability of the total score, which is estimated
y Cronbach alpha. Thus, a decrease of such a curve after
scenarios (N = 797).
PCA 2 PCA 3 Original*
C1 C1 C1
C1 C1 C1
C1 C1 C1
Excluded [42]
C2 C2 C2
C2 C2 C2
C2 C2 C3 & C2
C2 C2 C4
C3 C3 C1 & C3
C3 C3 C1
Excluded [42]
C3 — C3
Replaced by MacD13&14 [42]
C3 C3 C1 & C3
C3 C3 C1
C3 C3 C3
C4 C4 C4
Excluded [42]
C3 C3 C4
C4 C4 C4
C1 C3 C1 & C3
C4 C3 C1
C4 C3 C3 & C4
C4 C4 C4
C4 C4 C4 & C3
C3 C3 C3
chell et al., referred to as C2 here in the final column to facilitate
C3 here in the final column); C4: Embarrassment (F3 in Mitchell et al.
ata were deleted; PCA 2: pseudocorrelation matrix computed after
hich the item loaded in the original UK data, here shown in the finalthree
CA 1
C1
C1
C1
C2
C2
C2
C4
C3
C3
C3
C3
C3
C3
C4
C3
C4
C3
C3
C3
C4
C4
C3
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114 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 – 1 2 0dded variable did not constitute a one-dimensional set with
he other variables.
After an initial rough clustering of items based on previous
orced PCA with Varimax rotation, Cronbach alpha coefficient
urves [49,50] were used to identify a precisely one-dimensional
luster of items. One single dimension (all items of the cluster
easuring thesameunderlyingconstruct)means that theabove
urvesare increasingmonotonically.Otherwise, itemsshouldbe
llocated to another subscale. However, because these results
re influenced by sample fluctuations, they should be inter-
reted cautiously, especially when subscales contain few items.
etailed information can be found at: 10.1016/j.jval.2010.10.027.
Coefficient curves were plotted with all countries combined.
astly, a correlation matrix was computed relating question-
aire items to constructs (an item was expected to be more
ighly correlated with its own construct than with others). The
oodness of fit of the final multidimensional measurement
odel (parallel model within each subscale) was tested using
ASProcCalis, and, successively, for eachcountry.Nosignificant
eparture from themodel was obtained. All subscales were cal-
ulated using impact ratings weighted by importance ratings to
stimate the overall average-weighted impact score to reflect
ach individual patient’s view of the effects of MD on their QoL.
Construct validity was established by matching the pre-
icted relationships between derived constructs with clinical
r psychological attributes. The NEI-VFQ-25 has been shown
o be sensitive to VA in the BE and the WE, independently,
ith 10/20 and 10/100 as VA thresholds for BE andWE, respec-
ively [18]. Construct validity was checked by comparing a
ubset of patients with good VA (BE  10/20 andWE  10/100)
ersus patients with poor VA (BE 10/20 and WE 10/100).
omparisons were performed using analysis of variance.
Sensitivities ofMacDQoL andNEI-VFQ-25 to VA differences
ere estimated in those patients with measurements on both
nstruments. Differences between good and poor VA popula-
ions were obtained by dividing the corresponding VA ranges
dispersion indicator) of the total population. To allow com-
arison, both MacDQoL and NEI-VFQ-25 questionnaires were
ormalized, 0 being the worst and 100 the best patient-re-
orted outcome, after having weighted the scores as recom-
ended by the instrument authors.
All statistical tests were interpreted two-sided with alpha
xed at 5%. Alpha adjustment for test multiplicity was not per-
ormed.
esults
total of 797 patients were included in the PCA (France: 120;
taly: 126; Germany: 139; and the United States: 412). Their
ean age was 76.8 years, and 55% were women. Mean BE VA
as 0.38 LogMAR (51.9% 10/20) and WE VA 0.94 LogMAR
65.1%10/100). The proportion of patients with BE VA10/20
nd WE VA 10/100 was 40.3%, and that with BE VA 10/20
nd WE VA 10/100 was 23.3%. No major differences were
ound among countries.
Strong correlations between the 22 items (r0.50) and fac-
or loadings 0.48 on a forced one-factor analysis supported ihe use of an average weighted impact score. The overall
ronbach alpha curve increases steadily (Fig. 1) to 0.94.
Table 1 describes the principal component analysis results
ccording to the original analysis [42] and three scenarios (pa-
ients with missing data were deleted; pseudocorrelation ma-
rix computed after pairwise deletion; suppression of item #12,
olidays),with all countries pooled together. Oneof the analyses
as conducted without item #12 to document the impact of its
igh percentage of missing data (32.1%) on the factorial struc-
ure. The factorial structure was very close to that reported by
itchell et al. [42] (last column of Table 1), and the three anal-
ses produced similar results, except for items 10, 15, 19, and
2. The first axis explained 48.80% to 48.88% of the variance
nd comprised questionnaire items 1 (Household tasks), 2
Personal affairs), 3 (Shopping), and 21 (Independence shared
ith axis 3). The second axis explained 5.99% to 6.39% of the
ariance and included questionnaire items 5 (Personal rela-
ionship), 6 (Family life), 7 (Social life), and 8 (Physical appear-
nce shared with axis 4). The third axis explained 4.20% to
.48% of the variance and included questionnaire items 9
hrough 16 (9, Do physically; 10, Get out and about; 11, Long
ourneys; 12, Holidays; 13 through 14, Leisure activities and
obbies; 15, Self-confidence; 16, Motivation); items 19 (Future)
nd 26 (Enjoy nature); and items 22 (Do for others) and 23
Mishaps). The two last items were shared with axis 4. The
ourth axis explained 4.00% to 4.10% of the variance and in-
luded questionnaire items 17 (People’s reaction), 20 (Fi-
ances), 24 (Enjoy meals), 25 (Time taken), and three items
hared with the other axes, above. Analyses per country
howed minor variations of the models described.
Questionnaire items belonging to more than one construct
ere allocated to whichever construct they best contributed
o, demonstrated by a monotonic increment of Cronbach al-
ha curve. Questionnaire item 8 (Physical appearance) was
llocated to construct C4 (Embarrassment); questionnaire
ig. 1 – Overall weighting score, Cronbach alpha curve (N =
97). The Dxx labels on the curve identify the item
xcluded to construct the Cronbach alpha curve. Starting
rom the right to the left, the Dxx item contributing the
ost to the increase of the Cronbach alpha curve is
emoved from it, followed by the next greatest contributing
tem, until two items remain. When all items belong to the
core, this curve is expected to increase.tems 21 (Independence), 22 (Do for others), and 23 (Mishaps)
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115V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 – 1 2 0o construct C3 (Activities/capabilities). Step-by-step Cron-
ach curve analyses showed that item 20 (Finances) produced
deterioration in Cronbach alpha of axis 4 and could not be
ncorporated into any other construct without some damage
o internal reliability. Results of the final Cronbach alpha
urves are presented in Figure 2, where all alpha values were
0.77 (Table 2). Cronbach alpha curveswere computed in each
ountry and showed good reliability in each country. Cron-
ach alpha varied between countries from 0.94 to 0.95 for the
verall score, from 0.79 to 0.84 for the Essential task score,
rom 0.75 to 0.84 for the Family/social life score, from 0.92 to
.93 for the Activities/capabilities score, and from 0.71 to 0.81
or the Embarrassment score.
PCA and Cronbach alpha identified factors described by the
ollowing four constructs: Essential tasks (C1: questionnaire
tems 1, 2, and 3); Family/social life (C2: questionnaire items 5,
, and 7); Activities/capabilities (C3: questionnaire items, 9, 10,
2, 13/14, 15, 16, 19, 21, 22, 23, and 26); and Embarrassment (C4:
uestionnaire items 8, 17, 24, and 25). Questionnaire item 20,
elating to Finance, was not associated with any construct
ecause a differential item functioning by country was iden-
ified: it works well within the Embarrassment set of items
C4) only with the US sample.
Table 2 presents the correlation coefficients between ques-
ionnaire items and constructs. All coefficients lay between
.36 and 0.87, and all were statistically significant (P 0.0001).
hen the correlations between the construct without the
tem and the item were analyzed and compared with other
Fig. 2 – Relationships between Cronbach alpha values andorrelations, two items (7 and 25) had ahigher correlationwith hnother construct. The discrepancy was very minor for item 7
Social life) and a bit stronger for item 25 (Time taken). Figure 3
hows empirical distributions of the four constructs. Activi-
ies/capabilities approximated a normal distribution, but the
ssential tasks distribution was bimodal. Family/social life
nd Embarrassment were right-skewed.
Table 3 shows scores of the NEI-VFQ-25 and MacDQoL for
he set of patients assessed by both instruments. Patientswith
ood vision (BE 10/20 and WE 10/100) were compared with
hose exhibiting poor vision (BE 10/20 and WE 10/100). Pa-
ients with good vision produced significantly better overall
cores than those with poor vision (MacDQoL P  0.0001; NEI-
FQ-25 P  0.0001). In the overall population, 6 of the 13 NEI-
FQ-25 scores were lower than 50, the middle of the extreme
anges (0: worst visual function to 100: best visual function):
eneral health, General vision, Near vision, Mental health,
ole limitations, andDriving. Three of the fiveMacDQoL scale/
ubscale scores were lower than 50 (0  greatest negative im-
act on QoL, 100  most positive impact on QoL): Overall
eighted score, Essential tasks, and Activities/capabilities.
hen comparing the two groups of vision severity, the differ-
nces (the mean of the good vision group minus the mean of
he poor vision group) observed with the NEI-VFQ-25 varied
etween0.21 (General health) and 22.87 (Driving) and for the
acDQoL between 4.96 (Family/social life) and 13.62 (Essential
asks). Lastly, variation coefficients of MacDQoL were always
ower than 50.5, the Embarrassment scores being the lowest
30.63), suggesting a good ability to detect changes, if they
tionnaire items underlying MacDQoL constructs (N = 797).quesave occurred.
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nd NEI-VFQ-25 scores. As expected, the four MacDQoL sub-
cale scores were highly correlated (all r2 0.58) with each
ther but correlated only modestly with NEI-VFQ scores. Low
2 (0.3) was reported between all MacDQoL subscale scores
nd two NEI-VFQ-25 scores, General health and Ocular pain.
oderate correlations (0.3  r2  0.4) were found between
hree MacDQoL subscale scores (Essential task, Family/social
ife, Activities/capabilities) and two NEI-VFQ-25 scores (Color
ision, Peripheral vision). The Family/social life score was the
east often correlated to the NEI-VFQ-25 scores of all the four
acDQoL subscale scores.
iscussion
rincipal components analyses supported by one-dimen-
ional clustering of items using Cronbach Alpha curves of
MD patient samples drawn from American, French, Italian,
nd German populationswere performed to build one-dimen-
ional and well-separated MacDQoL simple subscales. Our re-
ults confirm with an international set of data the factorial
tructure of the MacDQoL, as established initially in a sample
f UK patients, and provide newly identified subscales coher-
nt with that factorial structure. A total of 797 patients con-
ributed to the validation, about one-half of whom partici-
ated in a clinical trial conducted in the United States, with
he remainder from a cross-sectional survey performed in
hree European countries. Our global results were very similar
Table 2 – Correlation coefficients between MacDQoL question
Essential tasks Famil
Essential tasks (  0.82)
MacD1 Household tasks 0.84
MacD2 Personal affairs 0.87
MacD3 Shopping 0.87
Family/social life (  0.82)
MacD5 Personal relationship 0.42
MacD6 Family life 0.52
MacD7 Social life 0.53
Activities/capabilities (  0.93)
MacD9 Do physically 0.62
MacD10 Get out and about 0.60
MacD12 Holidays 0.56
MacD1314 Leisure activities, Hobbies 0.61
MacD15 Self-confidence 0.57
MacD16 Motivation 0.58
MacD19 Future 0.44
MacD21 Independence 0.55
MacD22 Do for others 0.53
MacD23 Mishaps 0.53
MacD26 Enjoy nature 0.52
Embarrassment (  0.77)
MacD8 Physical appearance 0.49
MacD17 People’s reaction 0.36
MacD24 Enjoy meals 0.46
MacD25 Time taken 0.59
Those MTA (Multi-Trait Analysis) corrected-item subtotal coefficient
lation coefficients show higher correlations with other constructs (un
* Coefficient correlation between the item and its subscale score wito those reported by Mitchell et al. [42]. High inter-item corre- sations (estimated on 797 patients) supported the calculation
f a weighted overall score with high internal reliability and
ood sensitivity to visual acuity differences.
Patients included in this survey all had wet age-related
acular degeneration and all had CNV. Their AMD was the
evere wet form, which leads rapidly to visual impairment,
nd was therefore more serious than the AMD of patients in
he first MacDQoL validation. In one-quarter of our patients,
MDwas bilateral, as comparedwith 181 of 187 patients in the
riginal validation study. Nevertheless, the reliability was
ery similar, showing that the questionnaire is suitable for all
evels of severity of AMD.
US patients responded to the MacDQoL questions by tele-
hone, whereas the European patients completed the ques-
ionnaire themselves. However, the factorial structure of both
atient populationswas similar, showing thatMacDQoL ques-
ionnaires completed directly by patients or by telephone in-
erview produced a similar pattern of results.
Curves of Cronbach alpha values for all four constructs per
ountry showed very high internal reliability for American pa-
ients, but minor inconsistencies with Family/social life and
mbarrassment constructs with French and German patients.
uch small variations should be interpreted cautiously and in
elation to empirical data, i.e., declining slopes in the graphic
resentations were associated with variability and did not nec-
ssarilymean thatCronbachalphavalueswere trulydecreasing.
lso, the US sample was about two to three times larger than
amples from other countries and so dominated the analysis.
Cronbach alpha values of our four MacDQoL weighted con-
e items and constructs; MTA Multi-Trait Analysis (N = 797).
cial life Activities/capabilities Embarrassment MTA*
0.61 0.54 0.66
0.65 0.51 0.70
0.64 0.56 0.69
0.56 0.56 0.67
0.61 0.56 0.69
0.67 0.62 0.67
0.78 0.59 0.73
0.77 0.58 0.73
0.73 0.56 0.68
0.78 0.52 0.75
0.79 0.58 0.72
0.80 0.58 0.75
0.68 0.45 0.59
0.75 0.54 0.69
0.77 0.59 0.69
0.73 0.63 0.67
0.74 0.59 0.69
0.55 0.76 0.56
0.53 0.77 0.60
0.54 0.79 0.62
0.68 0.78 0.55
t are not underlined are for those items for which the regular corre-
ned in previous columns).
item score subtracted.nair
y/so
0.50
0.50
0.49
0.85
0.87
0.85
0.60
0.56
0.51
0.49
0.55
0.61
0.46
0.51
0.56
0.51
0.56
0.55
0.54
0.52
0.49
s tha
derlitructs (0.77 to 0.93) were less than the overall average
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117V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 – 1 2 0eighted impact score (0.95) of UK patients, probably because
f the reduced number of items.
A possible limitation of this study is that cognitive debrief-
ng interviews with patients to establish their understanding
f the items of the MacDQoL were only carried out in the de-
ign work in UK English and in the course of linguistic valida-
ion into Italian. No cognitive debriefing interviews were con-
ucted in France, Germany, or the United States before these
ata collections. No substantive changes were needed to the
talian questionnaire after cognitive debriefing, however, and
t is unlikely, but remains possible, that substantive changes
ould have been indicated in the French, German, or US En-
lish versions.
We identified four constructs with a very similar structure
o those reported by Mitchell et al. [42] and they were named
ssential tasks, Family/social life, Activities/capabilities, and
mbarrassment. Both Family/social life and Embarrassment
ere right-skewed.
Therefore, future studies in similar patients might trans-
orm the data or use non-parametric analysis to get more pre-
ise estimations. Strictly speaking, both scores had some floor
ffect. However, we would not want to drop items that were
etecting negative impact in 70% and 55% of patients, respec-
ively. In addition, Table 3, which gives differences between
hose with good vision and those with poor vision, shows that
mbarrassment has the second largest difference shown by
he four MacDQoL subscales. Therefore the size of the floor
ffect is not necessarily related to the ability of the subscales
Essential tasks score
0%
2%
4%
6%
8%
10%
12%
14%
16%
3 9 15 21 27 33 39 45 51 57 63 69 75 81 +
Median class score
Activities capabilities score
0%
2%
4%
6%
8%
10%
12%
3 9 15 21 27 33 39 45 51 57 63 69 75 +
Median class score
ig. 3 – Distribution functions of the four MacDQoL construct
mpact on quality of life) to 100 (greatest positive impact ono discriminate between groups. sWe are proposing the continued use of weighted scores,
ven for subscale scores. Trauer and Mackinnon [51] showed
hat weightings made no difference to life satisfaction mea-
ures, and it has been demonstrated that importance weight-
ngs add nothing to a diabetes treatment satisfactionmeasure
ecause all items were seen as important [52]. However, im-
ortance ratings have been shown to be needed for the Mac-
QoL and relatedmeasures [37,40]. In theMitchell and Bradley
37] 2004 article, it was found that the full range of importance
cores was used for 14 of the 22 domains, showing that do-
ains considered very important to some individuals were
ot at all important to others. See Brose et al. [53] for further
iscussion of this issue.
The MacDQoL questionnaire appeared to be more specific
o VA impairment in MD patients than the NEI-VFQ-25 be-
ause the differences between good and poor vision groups
ere similar for the two scales despite the MacDQoL range
eing smaller. Four subscales may be relevant when evalu-
ting the impact of VA impairment on the MacDQoL, the
verall average weighted impact score, and subscale scores
or Essential tasks, Activities/capabilities, and Embarrass-
ent. It would appear that Family/social life was less sen-
itive to VA impairment than the other three MacDQoL sub-
cales.
Among the 4 scores, Embarrassment had weaker properties
han the others. The structure wasmore sensitive to the type of
CA; Cronbach alpha was lower although still satisfactory
0.70). However, its variation coefficient was the smallest, but
Family / social score
0%
5%
10%
15%
20%
25%
30%
35%
0 6 12 18 24 30 36 42 48 54 60 66 72 78 +
Median class score
Embarrassment score
0%
5%
0%
5%
0%
5%
3 9 15 21 27 33 39 45 51 57 63 69 75 +
Median class score
= 797). Scores normalized from zero (greatest negative
ity of life).1
1
2
2
s (N
qualensitivity to changes needs to be checked.
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ain and the four MacDQoL scores might be related to the fact
hat these two NEI-VFQ-25 dimensions have little relevance for
RMD.The Family/social life score of theMacDQoLwas the least
orrelated of the MacDQoL scores, with the NEI-VFQ-25 scores
uggesting that the impact of AMD on family and social life has
he least to dowith visual functioning,whereas responses to the
ssential tasks, Activities/capabilities, and Embarrassment sub-
cales are more closely related to visual function.
Table 3 – Comparison of MacDQoL and NEI-VFQ25 scores.
Instrument Construct Good visio
BE 10/20
WE 10/10
N Me
NEI-VFQ-25 Global score 174 50
NEI-VFQ-25 General health 174 40
NEI-VFQ-25 General vision 174 45
NEI-VFQ-25 Ocular pain 174 76
NEI-VFQ-25 Near vision 173 41
NEI-VFQ-25 Distance vision 173 49
NEI-VFQ-25 Social function 174 64
NEI-VFQ-25 Mental health 174 39
NEI-VFQ-25 Role limitations 174 39
NEI-VFQ-25 Dependency 174 51
NEI-VFQ-25 Driving 94 36
NEI-VFQ-25 Color vision 171 76
NEI-VFQ-25 Peripheral vision 173 60
MacDQoL Overall average weighted
impact score
174 48
MacDQoL Essential tasks 174 39
MacDQoL Family/social life 174 51
MacDQoL Activities/capabilities 174 40
MacDQoL Embarrassment 174 57
BE: best eye; WE: worst eye.
* MacDQOL and NEI-VFQ-25 scores were standardized to allow com
coefficient  standard deviation/mean.
Table 4 – Correlation matrix within MacDQoL scores (N = 7
Correlation coefficient MacDQoL Family/socia
essential tasks
MacDQol
Essential tasks 1 —
Family/social life 0.58 1
Activities/capabilities 0.73 0.71
Embarrassment 0.65 0.69
NEI-VFQ-25
Global score 0.59 0.53
General health 0.16 0.16
General vision 0.47 0.40
Ocular pain 0.20 0.25
Near vision 0.50 0.38
Distance vision 0.52 0.39
Social function 0.45 0.39
Mental health 0.54 0.55
Role limitations 0.51 0.46
Dependency 0.54 0.54
Driving 0.47 0.33
Color vision 0.35 0.36
Peripheral vision 0.38 0.34Correlation coefficients lower than 0.4 are underlined. NA, not available.The Finance item (20) was the only item to show clear differ-
nces in item functioning between the European countries and
heUnitedStates. It clusteredwellwith the Embarrassment con-
truct, but only with the US sample, so we decided to exclude it
rom the newly constructed subscales. Nonetheless, it remains
ery relevant and is included in the global score, and can be
nalyzed alone. It is understandable that Finances were per-
eived to be more impacted by macular disease in the United
tates than in France, Germany, or Italy, where national social
Poor vision Difference Variation
coefficient*BE 10/20
WE 10/100
good vision –
poor vision
N Mean Mean
89 41.22 9.07 41.85
89 40.73 0.21 46.86
89 38.65 7.10 39.84
89 76.40 0.54 32.32
89 32.12 9.14 58.91
89 36.19 13.06 54.70
89 53.65 11.29 44.88
89 31.62 7.66 63.71
89 30.62 8.82 66.66
89 38.21 13.75 63.39
40 13.44 22.87 98.20
89 65.73 10.59 37.00
88 51.14 9.41 47.93
89 38.39 9.75 35.89
89 25.73 13.62 51.01
87 46.41 4.96 40.41
89 31.33 9.47 47.55
89 47.12 10.58 31.30
ons. 0 is associated with a poor QoL, and 100 a high QoL. Variation
nd between MacDQoL and NEI-VFQ-25 (N = 360).
Activities/capabilities Embarrassment Overall
— — NA
— — NA
1 — NA
0.77 1 NA
0.63 0.64 0.68
0.15 0.14 0.17
0.50 0.48 0.53
0.24 0.29 0.27
0.49 0.46 0.52
0.50 0.54 0.55
0.46 0.50 0.51
0.64 0.62 0.68
0.57 0.50 0.59
0.58 0.61 0.64
0.51 0.42 0.51
0.38 0.53 0.45
0.39 0.44 0.44n
0
an
.29
.52
.75
.94
.26
.25
.94
.28
.44
.96
.30
.32
.55
.14
.35
.36
.80
.70
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119V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 0 – 1 2 0ecurity systems provide more financial support than in the
nited States.
When the present multinational trial and European survey
ere performed, only one, very expensive, drug (verteporfin)
as available to all participating countries, and this was 100%
eimbursed to all AMD patients showing choroidal neovascular-
zation. Accordingly, the impact of this medical cost would not
ave been noted by our patients. However, the costs of visual
mpairment are mostly borne by the individual/family and
ould have been noticed. These costs comprise mainly loss of
amily revenue and paid assistance for tasks formerly self-com-
leted, andareequal to thenationaldrugbudget (inFrance, Italy,
ermany, and the United Kingdom) [54,55].
onclusion
he factorial structure of the MacDQoL, observed among US,
rench, Italian, andGermanpatientswithwet AMD,was similar
o that published recently for UK patients. The MacDQoL is a
eliable instrument that has a good ability to discriminate pa-
ients with good or poor vision. Preliminary results suggest that
our MacDQoL constructs (Overall weighted score, Essential
asks, Activities/capabilities, and Embarrassment) might be at
east as sensitive as most NEI-VFQ-25 constructs. Whereas the
EI-VFQ captures the extent of general impairments to vision
unction, the MacDQoL goes beyond this to measure the partic-
lar impact of macular disease on QoL, taking account of indi-
idual differences in the relevance and importance of different
spects of life. The MacDQoL subscales identified here may
rove to be usefulmeasures for treatment evaluation in patients
ith AMD in addition to the overall average weighted impact
core.
ccess to MacDQoL
heMacDQoL questionnaires used in this work included the US
nglish version adapted from the original UK English dated Jan-
ary 31, 2002, and linguistic validations of the same UK English
ersion into German, Italian, and French byMapi Research Insti-
ute in Lyon in close collaboration with the copyright holder,
lare Bradley, PhD.
The MacDQoL, associated guidelines and information, and a
icense to use the questionnaire can be obtained from the copy-
ight holder, Clare Bradley, PhD, Professor of Health Psychology
t Royal Holloway, University of London, Egham, and Surrey,
W20 0EX, United Kingdom, via the website of Health Psychol-
gy Research Ltd.: www.healthpsychologyresearch.com.
upplementary Data
upplementary data associatedwith this article can be found, inhe online version, at 10.1016/j.jval.2010.10.027.E F E R E N C E S
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